Aurobindo Pharma receives USFDA nod for endometriosis treatment drug
New Delhi: Drug firm Aurobindo Pharma has received approval from the US health regulator to manufacture and market generic Norethindrone Acetate tablets in the American market.
The company has received the final nod from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets in the strength of 5 mg, Aurobindo Pharma said in a statement.
"The approved product has an estimated market size of USD 24 million for the 12 months ending November 2015 according to IMS," it added.
The company's product is generic version of Duramed Pharmaceuticals Aygestin tablets in the same strength, Aurobindo Pharma said.
"Norethindrone Acetate tablet is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea," it added.
The company has a total of 230 abbreviated new drug application (ANDA) approvals (199 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from the USFDA.
The company has received the final nod from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets in the strength of 5 mg, Aurobindo Pharma said in a statement.
"The approved product has an estimated market size of USD 24 million for the 12 months ending November 2015 according to IMS," it added.
The company's product is generic version of Duramed Pharmaceuticals Aygestin tablets in the same strength, Aurobindo Pharma said.
"Norethindrone Acetate tablet is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea," it added.
The company has a total of 230 abbreviated new drug application (ANDA) approvals (199 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.